Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Asian Brokers: A Competition Between Value and Growth

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Bottom-Up

East Money Information / Equity Bottom-Up

<p>East Money is the most actively traded A-share stock in 2020. It just reported its 1H2021 results. Unlike the traditional broker, it has a strong leverage on its online information platform which is well reflected in its latest financial results. As an unconventional broker and a member stock of the MSCI China A50 index, we think investors should follow the company closely.</p>

East Money is the most actively traded A-share stock in 2020. It just reported its 1H2021 results. Unlike the traditional broker, it has a strong leverage on its online information platform which is well reflected in its latest financial results. As an unconventional broker and a member stock of the MSCI China A50 index, we think investors should follow the company closely.

East Money 1H21: The Most Active A-Share that Beat the Market